SS-31

What Is SS-31 Peptide & What Is It Used For?

SS-31 peptide, also known as elamipretide or MTP-131, is a synthetic tetrapeptide with the sequence D-Arg-2′,6′-Dmt-Lys-Phe-NH₂. It is studied for its ability to concentrate selectively in the inner mitochondrial membrane and interact with cardiolipin, a phospholipid essential for mitochondrial structural integrity and electron transport chain (ETC) stability. Its identity within the longevity and anti-aging peptide category comes from this membrane-level mechanism rather than from receptor cascade activation or metabolic pathway signaling.

In research settings, SS-31 is evaluated for mitochondrial dysfunction, oxidative stress reduction, exercise tolerance, skeletal muscle protection, cardiac function, and renal injury models. Elamipretide, the drug form of SS-31, has been studied across cardiac, renal, skeletal muscle, and mitochondrial disease contexts.

As of June 2026, elamipretide is FDA-approved as Forzinity for Barth syndrome in patients weighing at least 30 kg. This approval is indication-specific and does not extend to longevity, exercise tolerance, or general mitochondrial dysfunction applications; research-grade SS-31 used outside approved labeling should be treated as investigational and jurisdiction-specific.

SS-31 and Mitochondrial Dysfunction: Mechanism of Action

SS-31 selectively concentrates in the inner mitochondrial membrane at concentrations approximately 1,000 times higher than in plasma, a pharmacokinetic property that underpins its mechanism of action. The central action is its interaction with cardiolipin:

• Cardiolipin’s role: This phospholipid is unique to the inner mitochondrial membrane, where it anchors cytochrome c and stabilizes ETC complexes.
• What goes wrong in aging and disease: Cardiolipin peroxidation leads to ETC complex disassembly, increased electron leak, and elevated mitochondrial reactive oxygen species (mROS) — a cascade that drives oxidative stress, impaired ATP production, and cellular damage.
• How SS-31 intervenes: By binding cardiolipin, SS-31 is studied for its ability to restore ETC efficiency, reduce mROS production, prevent cytochrome c release, and preserve mitochondrial membrane potential.

This mechanism positions SS-31 as a structural mitochondrial protector rather than a general antioxidant. Findings from preclinical models suggest SS-31 may reverse established mitochondrial dysfunction, and because mROS reduction has downstream anti-inflammatory and cellular protective effects, research interest spans cardiac, renal, skeletal muscle, and neurodegeneration models. The strength of evidence differs by indication — preclinical animal data are the strongest base across most tissue types, while human data are indication-specific and mixed.

SS-31 Peptide Benefits: Exercise Tolerance, Skeletal Muscle & Longevity

• Exercise tolerance: SS-31 has been studied in mitochondrial myopathy and related conditions where impaired ATP production affects physical performance. However, MMPOWER-3, a clinical trial evaluating outcomes such as six-minute walk distance and fatigue in primary mitochondrial myopathy, did not show a significant improvement over placebo at 24 weeks. Claims about exercise tolerance should therefore remain cautious and trial-specific.
• Skeletal muscle: Preclinical studies suggest potential benefit in aging-associated muscle dysfunction and mitochondrial disease models. Human translation remains limited.
• Cardiac function: Multiple clinical studies in heart failure populations have examined SS-31, including the MMAD trial. Results have shown tolerability but mixed efficacy.
• Renal protection: Supported primarily by preclinical and early clinical research. Human data are limited.
• Oxidative stress: mROS reduction is the most mechanistically established effect, with downstream relevance to inflammation, ATP availability, and cellular integrity across multiple tissue types.

Overall, SS-31 is best framed as a mitochondrial membrane-targeting research compound with strong mechanistic rationale, active clinical development, and indication-specific evidence gaps.

SS-31 Peptide Dosage & Administration

• Clinical trial IV dosing: Published human studies have used IV elamipretide dose ranges of 0.005–0.25 mg/kg in cardiac and renal research contexts, administered under controlled protocols with defined populations, monitoring protocols, and safety procedures. These should not be generalized into universal dosing recommendations.
• Practitioner-reported subcutaneous dosing: Ranges such as 1–10 mg daily are sometimes discussed, but these are extrapolated from preclinical data and should not be presented as validated human dosing protocols.

Storage and Handling

Lyophilized SS-31 typically requires cold storage, reconstitution with bacteriostatic water when appropriate, refrigeration at 2–8°C after reconstitution, and protection from light. Handling instructions should always be verified through supplier documentation and the certificate of analysis.

SS-31 Side Effects & Safety Profile

SS-31 has generally been described as tolerable in clinical studies, but safety conclusions depend on route, indication, duration, and study design:

• IV infusion: Mild infusion-related reactions, such as flushing or nausea, have been reported; these are typically rate-dependent and can be managed with slower infusion rates.
• Subcutaneous use: Local injection-site reactions (redness, tenderness, or swelling) are the most commonly reported effects and are generally mild and transient.
• Long-term subcutaneous safety gap: Most controlled human safety data come from regulated IV clinical study protocols, not subcutaneous administration outside approved labeling. This distinction should remain clear in all professional discussions.

SS-31 should not be described as universally safe even when short-duration studies report acceptable tolerability. Qualified professionals should review adverse event data, formulation quality, route-specific risks, medical history, and regulatory status before discussing SS-31 in any research protocol.

SS-31 vs MOTS-c, NAD & AOD

SS-31 is most appropriate in research contexts where mitochondrial structure, cardiolipin stability, oxidative stress at the membrane level, and ATP production are the primary questions. Understanding how it compares with related compounds helps clarify its unique position.

MOTS-c

SS-31 acts at the physical level of the inner mitochondrial membrane by binding cardiolipin and stabilizing the ETC structure. Practitioners who buy MOTS-c for AMPK-mediated metabolic signaling research are working with a mitochondrial-derived peptide that activates downstream metabolic enzyme pathways, influencing insulin sensitivity and exercise-mimetic responses.

The two compounds target mitochondrial aging through entirely distinct entry points (structural membrane protection versus metabolic signaling activation), making them highly complementary rather than interchangeable for comprehensive mitochondrial longevity research.

NAD

SS-31 targets mitochondrial membrane integrity at the structural level, functioning as an upstream defense against mROS generation. Practitioners who buy NAD for cellular repair and metabolic cofactor research are working with a compound that replenishes the cofactor pool powering sirtuin activity, PARP-mediated DNA repair, and mitochondrial biogenesis. SS-31 may be understood as preventing mitochondrial damage at its source, while NAD supports downstream repair and regenerative pathways.

Both target mitochondrial aging through different mechanisms, and a strong stacking rationale exists when both membrane protection and cofactor repletion are protocol priorities.

AOD

SS-31 and AOD 9604 address distinct research targets with limited mechanistic overlap. Practitioners who buy AOD for adipose-focused metabolic research are evaluating a compound that has been studied for fat metabolism and lipolysis via growth hormone fragment pathways.

SS-31 is studied for mitochondrial membrane protection, cardiac energetics, oxidative stress, and skeletal muscle function — a fundamentally different research domain. In comprehensive anti-aging metabolic protocols, the two may be relevant together when both mitochondrial protection and targeted fat metabolism are protocol objectives, but they should not be treated as alternatives. Doctor Medica’s staff can provide additional context on these comparisons and can guide practitioners on sourcing from qualified suppliers.

Legal Status of SS-31

As of June 2026, SS-31’s regulatory status by jurisdiction is as follows:

• United States: Elamipretide is FDA-approved as Forzinity for Barth syndrome in patients weighing at least 30 kg. This approval does not extend to research-grade SS-31 used for longevity, exercise tolerance, or general mitochondrial dysfunction protocols. SS-31 for non-approved indications remains subject to investigational, compounding, or research-use restrictions. Practitioners should consult current FDA guidance directly regarding compounding eligibility and 503A bulk substance status, as policy continues to evolve.
• Australia: SS-31 is not broadly marketed as a TGA-approved therapeutic for longevity or general mitochondrial support. Practitioners should verify the current local classification and the availability of compounding before any protocol discussion.
• WADA: SS-31 is not currently listed by name on the WADA Prohibited List; athletes should verify its current status independently, as the list is updated annually.

Where Can Practitioners Buy SS-31 Online?

Practitioners who choose to buy SS-31 online should confirm that any supplier serves qualified professionals only and provides documentation supporting a compliant research procurement decision. When evaluating how to purchase SS-31 from a verified source, practitioners should look for suppliers that provide a certificate of analysis, LOT number traceability, and clear purity documentation for each batch. These are minimum requirements for research-grade procurement and are not optional in a compliant sourcing workflow.

Practitioners who want to order SS-31 for licensed research protocols can contact Doctor Medica’s staff for guidance on identifying qualified suppliers and obtaining the supporting documentation needed to make informed sourcing decisions. Doctor Medica connects licensed professionals with research-grade suppliers and does not substitute for jurisdiction-specific regulatory review.

FAQs

1. What is the SS-31 peptide?

SS-31 peptide is a synthetic tetrapeptide also known as elamipretide or MTP-131. It selectively targets the inner mitochondrial membrane and interacts with cardiolipin, making it mechanistically distinct from other longevity and anti-aging peptides. In research contexts, it is studied for its effects on mitochondrial membrane protection, oxidative stress reduction, and tissue energetics.

2. What does the SS-31 peptide do?

SS-31 binds cardiolipin in the inner mitochondrial membrane and is studied for its potential to stabilize ETC structure, reduce mitochondrial reactive oxygen species, and preserve mitochondrial membrane potential. This mechanism may limit the downstream cascade of oxidative stress, impaired ATP production, and cellular damage. Evidence is strongest in mechanistic and preclinical models, with mixed but growing human clinical data.

3. What is the SS-31 peptide used for?

SS-31 is used in research discussions involving mitochondrial dysfunction, exercise tolerance, skeletal muscle energetics, cardiac function, renal protection, and oxidative stress. Elamipretide holds FDA approval as Forzinity for Barth syndrome in patients weighing at least 30 kg. Other research-grade uses should be treated as investigational unless specifically approved in the relevant jurisdiction.

4. What is the SS-31 dosage?

SS-31 peptide dosage depends on whether the discussion refers to clinical trial data or practitioner-reported research use. Human clinical studies have used controlled IV dose ranges of 0.005–0.25 mg/kg under regulated protocols. Subcutaneous research-use discussions cite practitioner-reported ranges of approximately 1–10 mg daily, but no validated subcutaneous protocol should be presented as equivalent to clinical trial dosing.

5. What are the SS-31 peptide benefits?

SS-31 peptide benefits discussed in research include support for mitochondrial function, reduction of oxidative stress, skeletal muscle protection, cardiac energetics, and exercise tolerance. Clinical studies show mixed results depending on the indication, including limited benefit in MMPOWER-3 for primary mitochondrial myopathy. Benefits should be evidence-tiered and cited with specific trial attribution rather than generalized across all applications.

6. How does SS-31 compare to MOTS-c?

SS-31 and MOTS-c are both mitochondrial research peptides, but they work through different mechanisms. SS-31 binds cardiolipin and protects mitochondrial membrane structure, while MOTS-c activates AMPK-mediated metabolic signaling pathways. They may be highly complementary in mitochondrial longevity research, but should not be treated as interchangeable.

7. Is SS-31 FDA-approved?

Elamipretide is FDA-approved as Forzinity for Barth syndrome in patients weighing at least 30 kg. This does not make research-grade SS-31 broadly approved for longevity, exercise tolerance, or general mitochondrial dysfunction protocols. Practitioners should verify current regulatory status, indication, formulation, and jurisdiction-specific restrictions before any sourcing or protocol discussion.

References

1. Sabbah HN, Alder NN, Sparagna GC, et al. Contemporary insights into elamipretide’s mitochondrial mechanism of action and therapeutic effects. Biomed Pharmacother. 2025;187:118056. doi:10.1016/j.biopha.2025.118056
2. Karaa A, Bertini E, Carelli V, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023;101(3):e238-e252. doi:10.1212/WNL.0000000000207402
3. Zhao C, Zhuang X, Gao J. Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval. Drug Discov Ther. 2026;19(6):435-436. doi:10.5582/ddt.2025.01111
4. Chatfield KC, Sparagna GC, Chau S, et al. Elamipretide Improves Mitochondrial Function in the Failing Human Heart. JACC Basic Transl Sci. 2019;4(2):147-157. Published 2019 Apr 29. doi:10.1016/j.jacbts.2018.12.005

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.